ABT · Full Picture

ABBOTT LABORATORIES — the full picture

Earnings window · 2026-07-07 to 2026-09-24 · anchored on the 10-Q report

One earnings window, everything merged: the filing, the call, press releases and news digests, folded into ranked threads.

What to look at first

  1. Gross Margin Drivers · Gross marginPriority 81
    -35.4% operating_income; 3 sources (news, press_release, sec_filing); 5 forward row(s); quote_verified
    Abbott’s estimated annual amortization expense for intangible assets: approximately $2.6 billion in 2026, $2.3 billion in 2027, $1.8 billion in 2028, $1.7 billion in 2029, and $1.5 billion in 2030.
  2. Capital Return Program · Buybacks & dividendsPriority 77
    +0.0% operating_income; 3 sources (news, press_release, sec_filing); 3 forward row(s); quote_verified
    Abbott Laboratories has completed a $1.35 billion share buyback, repurchasing over 14 million shares.
  3. Operating Expense Trends · Operating expenses (SG&A)Priority 74
    -26.9% operating_income (realized); 2 sources (press_release, sec_filing); quote_verified
    SG&A expenses increased $934 million to $4.0 billion in the second quarter (30.3 percent) and increased $1.6 billion to $7.8 billion in the first six months (26.2 percent) in 2026, primarily due to the addition of Exact Sciences and related integration expenses.
  4. Debt and Liquidity Position · Liquidity & cash positionPriority 73
    -20.7% liability (realized); quote_verified
    The Exact Sciences acquisition was funded primarily through the issuance of $20.0 billion of long-term debt in March 2026, with the remainder funded by cash on hand.
  5. Operating Cash Flow and Capex · UnclassifiedPriority 73
    -18.9% cash (realized); quote_verified
    Net cash used in investing activities for the six months ended June 30, 2026: $(20,997) million and for the six months ended June 30, 2025: $(1,052) million.
  6. Exact Sciences Acquisition · M&A and divestituresPriority 71
    +2.7% revenue; 2 forward row(s); quote_verified
    Abbott completed the acquisition of Exact Sciences on March 23, 2026 for approximately $20.6 billion.
  7. Revenue Performance and Mix · Revenue growth & mixPriority 70
    -13.4% net_income (realized); 3 sources (news, press_release, sec_filing); 1 forward row(s); quote_verified
    Worldwide Diagnostics sales in 2Q26: $3,092 million, up 42.3% on a reported basis and up 2.9% on a comparable basis versus 2Q25.
  8. Restructuring Charges · Restructuring & impairmentPriority 61
    -26.1% operating_income (realized); quote_verified
    2Q26 diluted earnings per share excluding specified items excludes net after-tax charges of $1.362 billion, or $0.78 per share, for intangible amortization, charges related to acquisitions, legal reserves, investment impairments, and other net expenses.
  9. Acquisition / Partnership / Divestiture · M&A and divestituresPriority 60
    2 sources (news, press_release); 3 forward row(s); quote_verified
    On March 23, 2026 Abbott acquired Exact Sciences and completed the acquisition on that date.
  10. Operating Margin Drivers · UnclassifiedPriority 59
    +10.4% assets (realized); quote_verified
    Goodwill reported at June 30, 2026: $35.2 billion and at December 31, 2025: $24.0 billion; goodwill increased by $11.4 billion in the first six months of 2026 due to the Exact Sciences acquisition.
  11. Infant Formula Litigation · Litigation & settlementsPriority 58
    -2.7% net_income; 2 sources (news, press_release); 5 forward row(s); quote_verified
    Abbott Laboratories has agreed to pay over $384 million to resolve allegations concerning contaminated infant formula, according to the U.S. Justice Department.
  12. Regulatory Risk · Regulatory action & investigationsPriority 58
    3 sources (news, press_release, sec_filing); 2 forward row(s); quote_verified
    In May 2026 Abbott secured CE Mark for Libre® Duo, the world's first dual glucose-ketone biowearable sensor.

Threads by pillar

Revenue & Demand Priority 82 · 7 threads

Costs & Margins Priority 89 · 5 threads

Capital & Balance Sheet Priority 86 · 4 threads

Strategy & Portfolio Priority 76 · 6 threads

Legal, Regulatory & Policy Priority 75 · 8 threads

Guidance & Outlook Priority 41 · 1 thread

Macro & Market Conditions Priority 44 · 3 threads

Unclassified Priority 87 · 5 threads

Expected impact by metric

metricforward netforward grossrealized
operating_income-38.2%+38.2%-60.0%
net_income-5.1%+5.1%-36.9%
revenue+4.5%+4.5%+22.4%
liability-1.7%+1.7%-25.1%
cash-0.5%+0.5%+14.8%
assets——+33.8%